Insider Transactions in Q2 2025 at Edgewise Therapeutics, Inc. (EWTX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
5,187
-19.37%
|
$82,992
$16.45 P/Share
|
|
May 02
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
4,276
-17.18%
|
$68,416
$16.45 P/Share
|
|
May 02
2025
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,930
-22.81%
|
$30,880
$16.45 P/Share
|
|
May 02
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,551
-7.73%
|
$24,816
$16.45 P/Share
|
|
May 02
2025
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,314
-1.6%
|
$21,024
$16.45 P/Share
|
|
May 02
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,691
-7.67%
|
$27,056
$16.45 P/Share
|
|
May 01
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+28.01%
|
-
|
|
May 01
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+29.5%
|
-
|
|
May 01
2025
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+38.11%
|
-
|
|
May 01
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+20.6%
|
-
|
|
May 01
2025
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+5.95%
|
-
|
|
May 01
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+19.11%
|
-
|
|
Apr 03
2025
|
Peter A. Thompson |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 03
2025
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 01
2025
|
Jonathan C Fox |
BUY
Grant, award, or other acquisition
|
Direct |
559
+4.67%
|
-
|